フォローフィードコミュニティでトレーダーや投資家とつながりましょう.
包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.
ターミナル モニターで株式と資産のウォッチリストを整理および監視します
LILLY (ELI) & COMPANY - REGARD_trial_ramucirumab LILLY (ELI) & COMPANY - REGARD_trial_ramucirumab PR Newswire London, October 15 Date:...
Date: June 19, 2012 For Release: Immediately Refer to: (317) 276-5795 Mark Taylor Lilly Declares Third-Quarter 2012 Dividend, Resumes Share...
Date: June 12, 2012 For Release: Immediately Refer to: (317) 276-5795 - Mark Taylor (Lilly Corporate) 86-10-59042059 - Connie Li (Lilly China...
90-week data suggest sustained glucose reduction and weight loss with investigational SGLT-2 inhibitor, empagliflozin Study evaluating the...
Post-hoc analysis of linagliptin phase 3 data in adults with type 2 diabetes and albuminuria presented New analysis presented at American...
Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company present new linagliptin data at American Diabetes Association's 72nd...
Media Contacts: Lilly: Sonja Popp-Stahly, +1 317-655-2993, spopp-stahly@lilly.com Incyte: Pam Murphy, +1 302-498-6944, pmurphy@incyte.com Lilly...
Date: June 4, 2012 For Release: Immediately Refer to: (317) 276-5795 - Mark E. Taylor Dr. William G. Kaelin Jr. Elected to Lilly Board of...
Date: June 1, 2012 For Release: Immediately Refer To: Keri McGrath-Happe, +1 (317) 370-8394, mcgrath_happe_keri_s@lilly.com Amyvidtm (Florbetapir...
Date: May 31, 2012 Refer to: Eliza Merves Makovsky + Company Inc. for Kowa Pharmaceuticals America, Inc. Office (212) 508-9631 Mobile (908...
Jentadueto® (linagliptin/metformin hydrochloride) tablets recommended for approval in the treatment of adults with type 2 diabetes in Europe...
Date: May 22, 2012 For Release: Embargoed until May 22, 2012, 8:00 AM EDT Refer to: +1 317.701.4007 - Kelley Murphy Lilly Diabetes Presents Phase...
Issue Date: May 14, 2012 Media Alert Media Contacts: Amy Sousa (Lilly) Office: (317) 276-8478 Mobile: (317) 997-1481 Neil Hochman (TogoRun...
Date: April 25, 2012 For Release: Immediately Refer to: (317) 276-5795 - Mark E. Taylor (Media) (317) 655-6874 - Philip Johnson (Investors) Lilly...
ご覧いただいた銘柄が下記のボックス内に表示されますので、過去閲覧した銘柄情報に簡単にアクセスすることができます。
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約